Stem definition | Drug id | CAS RN |
---|---|---|
steroids for topical use, acetal derivatives | 633 | 126544-47-6 |
Dose | Unit | Route |
---|---|---|
0.20 | mg | N |
0.16 | mg | Inhal.aerosol |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2.90 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 33.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.04 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 20, 2006 | FDA | TAKEDA GMBH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 796.57 | 69.32 | 136 | 152 | 11178 | 2346619 |
Obstructive airways disorder | 338.59 | 69.32 | 50 | 238 | 1323 | 2356474 |
Dyspnoea | 306.32 | 69.32 | 90 | 198 | 78643 | 2279154 |
Wheezing | 261.82 | 69.32 | 50 | 238 | 6334 | 2351463 |
Blood count abnormal | 240.86 | 69.32 | 40 | 248 | 2242 | 2355555 |
Cough | 213.24 | 69.32 | 57 | 231 | 33060 | 2324737 |
Therapeutic product effect incomplete | 136.26 | 69.32 | 32 | 256 | 10499 | 2347298 |
Blood test abnormal | 103.16 | 69.32 | 18 | 270 | 1300 | 2356497 |
Sleep apnoea syndrome | 100.88 | 69.32 | 19 | 269 | 2107 | 2355690 |
Productive cough | 100.02 | 69.32 | 22 | 266 | 5299 | 2352498 |
Drug ineffective | 97.11 | 69.32 | 42 | 246 | 101582 | 2256215 |
Limb injury | 79.47 | 69.32 | 16 | 272 | 2494 | 2355303 |
Sputum discoloured | 78.34 | 69.32 | 14 | 274 | 1152 | 2356645 |
Wound | 78.14 | 69.32 | 16 | 272 | 2712 | 2355085 |
Chest discomfort | 77.97 | 69.32 | 22 | 266 | 14573 | 2343224 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 471.05 | 73.03 | 76 | 84 | 4828 | 1741793 |
Obstructive airways disorder | 293.16 | 73.03 | 42 | 118 | 1032 | 1745589 |
Cough | 177.54 | 73.03 | 43 | 117 | 19154 | 1727467 |
Blood count abnormal | 174.12 | 73.03 | 28 | 132 | 1429 | 1745192 |
Wheezing | 151.12 | 73.03 | 29 | 131 | 4124 | 1742497 |
Therapeutic product effect incomplete | 131.27 | 73.03 | 27 | 133 | 5421 | 1741200 |
Dyspnoea | 105.82 | 73.03 | 36 | 124 | 52023 | 1694598 |
Drug ineffective | 87.27 | 73.03 | 33 | 127 | 63768 | 1682853 |
Pulmonary function test decreased | 85.59 | 73.03 | 13 | 147 | 433 | 1746188 |
Hypoxia | 83.49 | 73.03 | 19 | 141 | 5944 | 1740677 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 82.50 | 73.03 | 9 | 151 | 14 | 1746607 |
Sputum discoloured | 80.16 | 73.03 | 13 | 147 | 664 | 1745957 |
Source | Code | Description |
---|---|---|
ATC | R01AD13 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R03BA08 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids |
MeSH PA | D018926 | Anti-Allergic Agents |
MeSH PA | D005938 | Glucocorticoids |
MeSH PA | D006728 | Hormones |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Allergic rhinitis | indication | 61582004 | |
Asthma | indication | 195967001 | DOID:2841 |
Seasonal allergic rhinitis | indication | 367498001 | |
Asthma management | indication | 406162001 | |
Severe chronic obstructive pulmonary disease | off-label use | 313299006 | |
Mycosis | contraindication | 3218000 | DOID:1564 |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Inactive tuberculosis | contraindication | 11999007 | |
Epistaxis | contraindication | 12441001 | |
Disease caused by parasite | contraindication | 17322007 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Acute tuberculosis | contraindication | 25629007 | |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Operation on nose | contraindication | 88733004 | |
Bilateral cataracts | contraindication | 95722004 | |
Ophthalmic herpes simplex | contraindication | 186542001 | |
Osteopenia | contraindication | 312894000 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Nasal Candidiasis | contraindication | ||
Oropharyngeal Candidiasis | contraindication | ||
Nasal Trauma | contraindication | ||
Uncontrolled Bacterial Infections | contraindication | ||
Nasal Septal Ulcers | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.78 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
0.08MG/INH | ALVESCO | COVIS PHARMA BV | N021658 | Jan. 10, 2008 | RX | AEROSOL, METERED | INHALATION | 8371292 | Feb. 1, 2028 | MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD |
0.16MG/INH | ALVESCO | COVIS PHARMA BV | N021658 | Jan. 10, 2008 | RX | AEROSOL, METERED | INHALATION | 8371292 | Feb. 1, 2028 | MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD |
0.05MG/INH | OMNARIS | COVIS PHARMA BV | N022004 | Oct. 20, 2006 | RX | SPRAY, METERED | NASAL | 8371292 | Feb. 1, 2028 | TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER |
0.037MG/INH | ZETONNA | COVIS PHARMA BV | N202129 | Jan. 20, 2012 | RX | AEROSOL, METERED | NASAL | 8371292 | Feb. 1, 2028 | TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | Ki | 7.43 | WOMBAT-PK | CHEMBL | |||
SARS-CoV-2 | Virus | INHIBITOR | IC50 | 5.36 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
4027427 | VUID |
N0000179737 | NUI |
C0907850 | UMLSCUI |
D01703 | KEGG_DRUG |
416739001 | SNOMEDCT_US |
417420004 | SNOMEDCT_US |
274964 | RXNORM |
19358 | MMSL |
d05465 | MMSL |
4027427 | VANDF |
008829 | NDDF |
S59502J185 | UNII |
6546 | INN_ID |
DB01410 | DRUGBANK_ID |
CHEBI:31397 | CHEBI |
7469 | IUPHAR_LIGAND_ID |
C120481 | MESH_SUPPLEMENTAL_RECORD_UI |
CHEMBL2040682 | ChEMBL_ID |
6918155 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Alvesco | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5989 | AEROSOL, METERED | 80 ug | RESPIRATORY (INHALATION) | NDA | 16 sections |
Alvesco | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5990 | AEROSOL, METERED | 160 ug | RESPIRATORY (INHALATION) | NDA | 16 sections |
Omnaris | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6020 | SPRAY | 50 ug | NASAL | NDA | 13 sections |
Omnaris | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70515-701 | SPRAY | 50 ug | NASAL | NDA | 17 sections |
Alvesco | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70515-711 | AEROSOL, METERED | 80 ug | RESPIRATORY (INHALATION) | NDA | 17 sections |
Alvesco | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70515-712 | AEROSOL, METERED | 160 ug | RESPIRATORY (INHALATION) | NDA | 17 sections |
Zetonna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70515-737 | AEROSOL, METERED | 37 ug | NASAL | NDA | 17 sections |